Advanced search
1 file | 117.04 KB

The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage

(2002) ANNALS OF ONCOLOGY. 13(9). p.1331-1339
Author
Organization
Abstract
Two groups of patients, those treated for Hodgkin's disease and breast cancer, are particularly at risk of developing late myocardial damage, since radiotherapy (RT) techniques for both patient groups may include (large) parts of the heart, and adjuvant systemic therapy is frequently administered to these patients, in particular anthracycline-containing chemotherapy. Available literature on the monitoring and prediction of RT-induced and anthracycline-associated cardiac damage using nuclear medicine techniques is presented. Based on relevant studies, the risk of overall cardiac disease post-RT and overt congestive heart failure during anthracycline-containing chemotherapy is probably low. Conventional nuclear medicine imaging, i.e. myocardial perfusion scintigraphy, may be of complementary use to echocardiographical evaluation for routine follow-up after RT with modern techniques, in a subgroup of patients with known cardiovascular risk factors. Left ventricle ejection fraction (LVEF) measurements, as assessed by radionuclide angiography for the monitoring of anthracycline-associated cardiac injury, are not very sensitive and early detection will probably be enhanced by combining LVEF measurements with other cardiac function parameters. Also, it may be expected that nuclear medicine techniques using molecular radioligands will constitute an essential future step in the evaluation of subclinical cardiac injury afforded by the combined effect of RT and cardiotoxic chemotherapy.
Keywords
HODGKINS-DISEASE, DOXORUBICIN CARDIOTOXICITY, CONGESTIVE HEART-FAILURE, ADRENERGIC NERVOUS-SYSTEM, INDUCED MYOCARDIAL DAMAGE, LEFT-VENTRICULAR DYSFUNCTION, LONG-TERM SURVIVORS, BREAST-CANCER PATIENTS, radiotherapy-induced, SERIAL RADIONUCLIDE ANGIOCARDIOGRAPHY, prediction, nuclear medicine, anthracycline-associated, monitoring, cardiac damage, RADIATION-THERAPY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 117.04 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Goethals, Ingeborg, Olivier De Winter, Pieter De Bondt, Johan De Sutter, Rudi Dierckx, and Christophe Van De Wiele. 2002. “The Clinical Value of Nuclear Medicine in the Assessment of Irradiation-induced and Anthracycline-associated Cardiac Damage.” Annals of Oncology 13 (9): 1331–1339.
APA
Goethals, Ingeborg, De Winter, O., De Bondt, P., De Sutter, J., Dierckx, R., & Van De Wiele, C. (2002). The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage. ANNALS OF ONCOLOGY, 13(9), 1331–1339.
Vancouver
1.
Goethals I, De Winter O, De Bondt P, De Sutter J, Dierckx R, Van De Wiele C. The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage. ANNALS OF ONCOLOGY. 2002;13(9):1331–9.
MLA
Goethals, Ingeborg, Olivier De Winter, Pieter De Bondt, et al. “The Clinical Value of Nuclear Medicine in the Assessment of Irradiation-induced and Anthracycline-associated Cardiac Damage.” ANNALS OF ONCOLOGY 13.9 (2002): 1331–1339. Print.
@article{164539,
  abstract     = {Two groups of patients, those treated for Hodgkin's disease and breast cancer, are particularly at risk of developing late myocardial damage, since radiotherapy (RT) techniques for both patient groups may include (large) parts of the heart, and adjuvant systemic therapy is frequently administered to these patients, in particular anthracycline-containing chemotherapy. Available literature on the monitoring and prediction of RT-induced and anthracycline-associated cardiac damage using nuclear medicine techniques is presented. Based on relevant studies, the risk of overall cardiac disease post-RT and overt congestive heart failure during anthracycline-containing chemotherapy is probably low. Conventional nuclear medicine imaging, i.e. myocardial perfusion scintigraphy, may be of complementary use to echocardiographical evaluation for routine follow-up after RT with modern techniques, in a subgroup of patients with known cardiovascular risk factors. Left ventricle ejection fraction (LVEF) measurements, as assessed by radionuclide angiography for the monitoring of anthracycline-associated cardiac injury, are not very sensitive and early detection will probably be enhanced by combining LVEF measurements with other cardiac function parameters. Also, it may be expected that nuclear medicine techniques using molecular radioligands will constitute an essential future step in the evaluation of subclinical cardiac injury afforded by the combined effect of RT and cardiotoxic chemotherapy.},
  author       = {Goethals, Ingeborg and De Winter, Olivier and De Bondt, Pieter and De Sutter, Johan and Dierckx, Rudi and Van De Wiele, Christophe},
  issn         = {0923-7534},
  journal      = {ANNALS OF ONCOLOGY},
  keyword      = {HODGKINS-DISEASE,DOXORUBICIN CARDIOTOXICITY,CONGESTIVE HEART-FAILURE,ADRENERGIC NERVOUS-SYSTEM,INDUCED MYOCARDIAL DAMAGE,LEFT-VENTRICULAR DYSFUNCTION,LONG-TERM SURVIVORS,BREAST-CANCER PATIENTS,radiotherapy-induced,SERIAL RADIONUCLIDE ANGIOCARDIOGRAPHY,prediction,nuclear medicine,anthracycline-associated,monitoring,cardiac damage,RADIATION-THERAPY},
  language     = {eng},
  number       = {9},
  pages        = {1331--1339},
  title        = {The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage},
  url          = {http://dx.doi.org/10.1093/annonc/mdf318},
  volume       = {13},
  year         = {2002},
}

Altmetric
View in Altmetric
Web of Science
Times cited: